Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies
Article first published online: 31 JAN 2009
© 2009 John Wiley & Sons A/S
Acta Psychiatrica Scandinavica
Volume 120, Issue 1, pages 10–13, July 2009
How to Cite
Frye, M. A., Yatham, L., Ketter, T. A., Goldberg, J., Suppes, T., Calabrese, J. R., Bowden, C. L., Bourne, E., Bahn, R. S. and Adams, B. (2009), Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies. Acta Psychiatrica Scandinavica, 120: 10–13. doi: 10.1111/j.1600-0447.2008.01343.x
- Issue published online: 3 JUN 2009
- Article first published online: 31 JAN 2009
- Accepted for publication December 18, 2008
- thyroid-stimulating hormone;
Objective: To assess the relationship between depressive relapse and change in thyroid function in an exploratory post hoc analysis from a controlled maintenance evaluation of bipolar I disorder.
Method: Mean thyroid-stimulating hormone (TSH) and outcome data were pooled from two 18-month, double-blind, placebo-controlled, maintenance studies of lamotrigine and lithium monotherapy. A post hoc analysis of 109 subjects (n = 55 lamotrigine, n = 32 lithium, n = 22 placebo) with serum TSH values at screening and either week 52 (±14 days) or study drop-out was conducted.
Results: Lithium-treated subjects who required an intervention for a depressive episode had a significantly higher adjusted mean TSH level (4.4 μIU/ml) compared with lithium-treated subjects who did not require intervention for a depressive episode (2.4 μIU/ml).
Conclusion: Lithium-related changes in thyroid function are clinically relevant and should be carefully monitored in the maintenance phase of bipolar disorder to maximize mood stability and minimize the risk of subsyndromal or syndromal depressive relapse.